biote (NASDAQ:BTMD – Get Free Report) and Rock Creek Pharmaceuticals (OTCMKTS:RCPIQ – Get Free Report) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, profitability, analyst recommendations, risk, institutional ownership and dividends.
Analyst Ratings
This is a breakdown of current ratings for biote and Rock Creek Pharmaceuticals, as provided by MarketBeat.com.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
biote | 0 | 0 | 3 | 0 | 3.00 |
Rock Creek Pharmaceuticals | 0 | 0 | 0 | 0 | 0.00 |
biote currently has a consensus price target of $10.00, suggesting a potential upside of 119.30%. Given biote’s stronger consensus rating and higher probable upside, equities analysts plainly believe biote is more favorable than Rock Creek Pharmaceuticals.
Earnings and Valuation
Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
biote | $185.36 million | 1.34 | $3.32 million | $0.26 | 17.54 |
Rock Creek Pharmaceuticals | N/A | N/A | N/A | N/A | N/A |
biote has higher revenue and earnings than Rock Creek Pharmaceuticals.
Profitability
This table compares biote and Rock Creek Pharmaceuticals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
biote | 5.20% | -32.41% | 22.26% |
Rock Creek Pharmaceuticals | N/A | N/A | N/A |
Insider & Institutional Ownership
21.7% of biote shares are held by institutional investors. 13.9% of biote shares are held by company insiders. Comparatively, 0.9% of Rock Creek Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
biote beats Rock Creek Pharmaceuticals on 8 of the 9 factors compared between the two stocks.
About biote
biote Corp. operates in practice-building business within the hormone optimization space. It trains physicians and nurse practitioners in hormone optimization using bioidentical hormone replacement pellet therapy in men and women experiencing hormonal imbalance. The company offers Biote Method, a comprehensive end-to-end practice building platform that provides Biote-certified practitioners with the components developed for practitioners in the hormone optimization space comprising Biote Method education, training, and certification services; practice management software that allows Biote-certified practitioners to order, track, and manage hormone optimization product inventory and other administrative requirements; inventory management software to monitor pellet inventory; and information regarding available hormone replacement therapy products, as well as digital and point-of-care marketing support. It also sells dietary supplements under the Biote brand; and sterile pellet insertion kits that is used with hormone optimization therapies for male and female. The company was founded in 2012 and is headquartered in Irving, Texas.
About Rock Creek Pharmaceuticals
Rock Creek Pharmaceuticals, Inc. is an early stage life science company, which engages in the discovery, development, and commercialization of new drugs, formulations, and compounds that provide therapies for chronic and acute inflammatory diseases. It focuses on small molecule therapeutics that exhibit anti-inflammatory pharmacological characteristics. The company was founded by Jonnie R. Williams, Sr. on June 24, 1985 and is headquartered in Sarasota, FL.
Receive News & Ratings for biote Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for biote and related companies with MarketBeat.com's FREE daily email newsletter.